Access, Effectiveness, Safety, and Survival of Secukinumab in Patients With Axial Spondyloarthritis and Axial Psoriatic Arthritis: A Real-World Study in Argentina.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martire María Victoria, Marin Josefina, Maldonado-Ficco Hernán, Benegas Mariana, Giorgis Pamela, Vila Diego, Isnardi Carolina Ayelen, Gamba María Julieta, Flores-Trejo Javier Federico, Perez-Alamino Rodolfo, Chemez Antonio Jorge, Ferreyra-Garrott Leandro, Cosatti Micaela A, Buschiazzo Emilio Andrés, de Los Angeles Correa María, Aguila-Maldonado Rodrigo, Manases-Roldan Brian, Lizarraga Camila, Alfaro Maria Agustina, Morbiducci Julieta, Ingolotti Lia Valentina, Pendón Gisela, Nieto Romina Estefanía, Velloso María Sofía, Martinez-Muñoz Alejandro, Lloves-Schenone Nicolás, Zamora Natalia V, Saturansky Etel, Costi Ana Carolina, Haye-Salinas Maria Jezabel, Airoldi Carla Antonela, Granel Amelia
Аннотация
METHODS: In a multicenter, observational, retrospective cohort study, patients ≥ 18 years with axSpA or axPsA who had received ≥ 1 dose of SEC were included. The number of days between the request for the drug and the first application was calculated. Effectiveness was defined as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) < 4 at 6 months. Drug survival was analyzed using Kaplan-Meier curves and Cox regression analysis.
RESULTS: One hundred seventeen patients were included: 72 (61.5%) with axPsA and 45 (38.5%) with axSpA. Those having public health insurance presented a longer delay in receiving SEC (median 90 days [IQR 60-150]) vs those using the social security system (P = 0.01) and those with private health coverage (P = 0.009). Effectiveness of SEC after 6 months was achieved in 72/117 patients (61.5%): 44/72 patients with axial PsA (61.5%) and 28/45 patients with axSpA (62.2%; P = 0.91). The median SEC survival was 48 months (95% CI 32-63). The only factor associated with reduced survival was SEC as third-line treatment or higher (hazard ratio 3.43, 95% CI 1.11-11.10; P = 0.04). The incidence of AEs was 7.9 events/100 patients/year (95% CI 5-12).
CONCLUSION: The delay in receiving SEC was longer in patients with public health insurance. Patients using SEC as third-line or higher therapy had 3.4 times less survival. AEs were mild and no AEs of interest were observed.